Rare Disease in the Gulf: Where Patient Identification Is a Policy Decision

In the Gulf, two assumptions that anchor a Western rare-disease forecast do not hold. The first is that a smaller market means rarer disease. The second is that patient identification is slow, accidental, and outside anyone's control. Consanguinity enlarges the recessive-disease pool, and state-run screening turns identification into a policy lever whose outputs are published and movable. The result is a market that behaves differently enough that a scaled-down Western model gets it wrong in both directions.

Consanguinity enlarges the pool

The Gulf carries an unusually high burden of the autosomal-recessive disorders that make up much of the rare-disease universe, and the reason is marriage structure. First-cousin unions reach an estimated 25 to 30 percent of all Arab marriages and are still rising in some countries, against regional consanguinity rates the literature places between 25 and 70 percent. The genetic consequence is documented and specific: a relative abundance of recessive disorders that inverts the global pattern. It shows up in what screening measures. Saudi Arabia reports a spinal muscular atrophy carrier frequency of 2.6 percent against a global 1.25 to 2.0 percent, and it has the highest recorded frequency of mucopolysaccharidoses of any country. The pool is not a smaller version of the Western one. It is larger, per head.

The state makes the pool visible and movable

What makes the Gulf distinctive commercially is that the machinery to find patients is built by the state and its results are published. Saudi Arabia has run a mandatory premarital screening and genetic-counselling programme since 2004, and its six-year outcome is rare evidence that identification is a lever, not a constant: at-risk marriages fell by roughly 60 percent, voluntary cancellation of at-risk unions rose from 9 to 52 percent, and beta-thalassemia prevalence among those screened fell from 32.9 to 9.0 per 1,000. The national newborn-screening programme adds a standing identification system, and when 775,000 newborns were screened across a 16-disorder panel the overall detected incidence was 1 in 1,043, among the highest reported anywhere. The pool is measured, and the measuring changes it.

So the number moves on a schedule you can read

For a forecaster this is the crucial difference. In a Western market the diagnosis rate is left to the clinic and moves slowly and opaquely; in the Gulf it is set by screening policy, which is announced, funded, and reported. When Saudi Arabia added the enzyme assay for Pompe disease to its newborn panel in 2021, it created identified patients on a known timeline. The addressable pool grows with panel expansion and coverage, so the case-finding variable that governs any rare-disease forecast is, here, a policy variable a team can track rather than a black box.

But the market is concentrated and uneven

The Gulf is not homogeneous, and a credible model says so. Screening depth drops sharply outside Saudi Arabia and, increasingly, the UAE; only a handful of national programmes exist region-wide and panels range from a single disease to a couple of dozen, so measured incidence is a floor, not a ceiling. Diagnosis and advanced sequencing concentrate in a few tertiary centres, with KFSH&RC anchoring the Saudi ecosystem, and patients still report an average diagnostic odyssey of more than five years. That concentration is a bottleneck, and for a commercial team a small set of decision nodes. The market is distinct, not uniform.

The payer reframe

The economics follow the same logic. Because the state both bears most of the orphan-drug cost and runs the screening, identification and access are two ends of one policy. One modelling study put the annual saving from universal premarital genomic screening at roughly $8 million in the UAE and $324 million in Saudi Arabia against the cost of treating spinal muscular atrophy after birth, which reframes screening from a public-health expense into a payer-side asset. A rare-disease case built for the Gulf is argued on screening economics and government budget, not on a Western cost-per-QALY threshold.

The market is a function of how the state finds its patients

The Gulf is the clearest place to watch the rare-disease sizing discipline at work, because identification there is visibly engineered rather than left to chance. You model the number on screening policy, disease by disease and country by country, and you treat the region as its own market rather than a discount on the West. This is the rare-disease sizing discipline in its sharpest form: the size of the market is a function of how the state decides to find its patients.